By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded Cepheid and Myriad Genetics and reinstated Thermo Fisher Scientific as the investment firm revised estimates on a number of life science tools and molecular diagnostics vendors.

In a research report, analyst Isaac Ro upgraded Cepheid to a Buy rating, Myriad to Neutral, and reinstated Thermo Fisher at a Buy rating.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.